The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
 
“We also urge that the policy changes made by the final rule, first published in January 2017, remain substantially unchanged,” AHA said today in comments on the proposed rule. 
 
Facing deadlines for responding to a lawsuit brought by the AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems, HRSA Oct. 31 proposed the regulation to change the effective and compliance date to Jan. 1.
 
In its comments, AHA also urged the agency to make pricing information available to 340B hospitals and other participating providers online through a secure website, which is required by the final rule, “available as soon as possible after the effective date.”
 

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Perspective
Public
All of America’s hospitals and health systems, regardless of ownership status, size or location, provide a vast range of benefits, programs and essential…
Headline
The Healthcare Association of New York State Sept. 16 announced Bea Grause, R.N., its president and CEO, will retire in summer 2026. Grause was active for many…